Recent Updates
Recently added Catalysts

MK0954, /Duration of Treatment : 5 Years

Phase 3

Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) | Small molecule | Cardiovascular |Organon & Co.|Last Updated: Feb 15, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment496
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00338260Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)PHASE3 COMPLETED 496 — — Jun 1, 1995Nov 1, 2001Feb 15, 2022 - —
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Composite of cardiovascular death, fatal and nonfatal stroke, fatal and nonfatal myocardial infarction (heart attack)
Secondary Endpoints
cardiovascular death, stroke, myocardial infarction, all-cause mortality, hospitalization for heart failure, new-onset diabetes mellitus
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION
Interventions
NameTypeDescription
MK0954, /Duration of Treatment : 5 YearsDRUG -
Comparator : atenolol /Duration of Treatment : 5 YearsDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range55 Years — 80 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Age 55 to 80 years * Males and females * Hypertension (160-200/95-115 mm Hg * ECG evidence of left ventricular hypertrophy Exclusion Criteria: * Need for treatment with angiotensin converting enzyme inhibitors, or open- label angiotensin receptor blockers or beta-blockers * ...

Unlock Eligibility Criteria